Ursodiol and Colorectal Cancer or Dysplasia Risk in Primary Sclerosing Cholangitis and Inflammatory Bowel Disease: A Meta-Analysis

Hansen, Jonathan D; Kumar, Sonal; Lo, Wai–Kit; Poulsen, David; Halai, Umme Aiman; Tater, Kathy C.

doi:10.1007/s10620-013-2772-0

Cited by 42 publications

(16 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A few early observational studies and two recent meta-analyses suggest UDCA may prevent CRC in IBD, particularly in those patients who also have primary sclerosing choleangitis (PSC). 138142, 143 However, some data suggest that high-doses of UDCA may actually increase the risk of CRC in UC patients with PSC. 144 But again, its strong biologic plausibility supports its continued investigation for use in IBD to reduce the risk of CRC.…”

Section: Current State Of the Fieldmentioning

confidence: 99%

Molecular cancer prevention: Current status and future directions

Maresso

Tsai

Brown

et al. 2015

CA A Cancer J Clinicians

View full text Add to dashboard Cite

The heterogeneity and complexity of advanced cancers strongly supports the rationale for an enhanced focus on molecular prevention as a priority strategy to reduce the burden of cancer. Molecular prevention encompasses traditional chemopreventive agents as well as vaccinations and therapeutic approaches to cancer-predisposing conditions. Despite challenges to the field, we now have refined insights into cancer etiology and early pathogenesis; successful risk assessment and new risk models; agents with broad preventive efficacy (e.g., aspirin) in common chronic diseases, including cancer; and a successful track record of more than 10 agents approved by the FDA for the treatment of precancerous lesions or cancer risk reduction. The development of molecular preventive agents does not differ significantly from the development of therapies for advanced cancers, yet has unique challenges and special considerations given that it most often involves healthy or asymptomatic individuals. Agents, biomarkers, cohorts, overall design, and endpoints are key determinants of molecular preventive trials, as with therapeutic trials, although distinctions exist for each within the preventive setting. Progress in the development and evolution of molecular preventive agents has been steadier in some organ systems, such as breast and skin, than in others. In order for molecular prevention to be fully realized as an effective strategy, a number of challenges to the field must be addressed. Here we provide a brief overview of the context for and special considerations of molecular prevention along with a discussion of the results of major randomized controlled trials.

show abstract

Section: Current State Of the Fieldmentioning

confidence: 99%

Molecular cancer prevention: Current status and future directions

Maresso

Tsai

Brown

et al. 2015

CA A Cancer J Clinicians

View full text Add to dashboard Cite

show abstract

“…As for colorectal cancer (CRC), the real impact of the use of UDCA remains unclear, with two studies suggesting a protective effect (92,93) , four studies noting no impact (94)(95)(96)(97) and one study indicating increased risk of CRC in UDCA users (98) . Recent meta-analysis found no association between the use of UDCA and the risk of CRC or dysplasia in adults with PSC and IBD (99) . Reflecting the controversy, while the American guidelines do not recommend the use of UDCA as a prophylaxis agent against CRC (75) , the European guidelines suggest its use for high-risk patients (those with extensive colitis, positive family history or previous CRC), although it recognizes that there is limited evidence (68) .…”

Section: Pharmacological Treatment Of Pscmentioning

confidence: 99%

Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver

Bittencourt

Cançado

Couto

et al. 2015

Arq. Gastroenterol.

View full text Add to dashboard Cite

-In order to draw evidence-based recommendations concerning the management of autoimmune diseases of the liver, the Brazilian Society of Hepatology has sponsored a single-topic meeting in October 18th, 2014 at São Paulo. An organizing committee comprised of seven investigators was previously elected by the Governing Board to organize the scientific agenda as well as to select twenty panelists to make a systematic review of the literature and to present topics related to the diagnosis and treatment of autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cirrhosis and their overlap syndromes. After the meeting, all panelists gathered together for the discussion of the topics and the elaboration of those recommendations. The text was subsequently submitted for suggestions and approval of all members of the Brazilian Society of Hepatology through its homepage. The present paper is the final version of the reviewed manuscript organized in topics, followed by the recommendations of the Brazilian Society of Hepatology.

show abstract

“…(67) However, more recent meta-analyses of population based studies have suggested that a chemoprevention benefit may not exist for all patients, particularly when considering the dose of UCDA used. (68, 69) This lack of benefit with prior chemoprevention studies may be in part due to variability in disease activity, extent, and presence of established risk factors, or the non-specific mechanism through which these agents inhibit inflammation and modulate cancer risk.…”

Section: Chemopreventionmentioning

confidence: 99%

Colorectal Cancer and Dysplasia in Inflammatory Bowel Disease: A Review of Disease Epidemiology, Pathophysiology, and Management

Dulai

Sandborn

Gupta

2016

Cancer Prevention Research

153

108

View full text Add to dashboard Cite

Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel diseases (IBD) characterized by recurrent episodes of mucosal inflammation. This chronic mucosal inflammation has several potential consequences, one of which is the occurrence of colitis associated colorectal cancer (CRC). Over the past decade our understanding of the epidemiology, pathophysiology, and overall approach to diagnosing and managing colitis associated CRC, has grown considerably. In the current review article, we outline these advancements and highlight areas in need of further research.

show abstract

Ursodiol and Colorectal Cancer or Dysplasia Risk in Primary Sclerosing Cholangitis and Inflammatory Bowel Disease: A Meta-Analysis

Cited by 42 publications

References 27 publications

Molecular cancer prevention: Current status and future directions

Molecular cancer prevention: Current status and future directions

Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver

Colorectal Cancer and Dysplasia in Inflammatory Bowel Disease: A Review of Disease Epidemiology, Pathophysiology, and Management

Contact Info

Product

Resources

About